兴奋剂
敌手
受体
内分泌学
内科学
肥胖
减肥
B2受体
医学
药理学
化学
缓激肽
作者
Aaron Novikoff,Timo D. Müller
标识
DOI：10.1016/j.tem.2024.04.016
摘要
Unimolecular co-agonists at the GLP-1/GIP receptors have recently achieved remarkable anti-obesogenic feats; yet, in a recent Phase 1 clinical trial, Véniant and colleagues report astounding body-weight loss, and an appreciable safety profile, in participants with obesity using the GLP-1R agonist/GIPR antagonist AMG 133.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
小花排草
乐乐乐乐乐乐
矛头蝮
MMMMM
rgb001
guo
鬼见愁
eric888
核桃
COSMAO
彩虹儿
比比谁的速度快
GingerF
Civen
打卡下班
不想干活
从容芮
遇上就这样吧
忧心的曼凝
yydragen
皖公网安备34019202002308
